Abstract
Background and study aim: Egypt is one of the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 6.3%. Applying best treatment protocol has a great impact on the national disease burden. DAAs open the door to decrease HCV prevalence as well as to treat infected subjects. Patients and Methods: In this study 1000 patients treated by Pegylated interferon, Sofosbuvir and weight adjusted Ribavirin. Another group of 1000 patients treated by Sofosbuvir and weight adjusted Ribavirin. Results: Two groups showed sustained virological response : 90.1% and 72.3% respectively. Both groups approved that previous treatment status and viral load has no impact on response prediction. Both showed that males are more likely to respond than females. Conclusion: Addition of Direct Acting Antivirals (DAAs), like sofosbovir, to the standard treatment with interferon and ribavirin improved the duration of the treatment and the sustained virological response (SVR). Treating of cirrhotics byPEGINF+SOF+RBV and SOF+RBV leads to decrease success rates. Validation of SVR once will be a golden rule.
Highlights
The World Health Organization has declared hepatitis C a global health problem, with approximately 3% of the world’s population infected with hepatitis C virus (HCV)
Sustained virological response in Egyptian patients treated with PEGIFN alfa-2a and ribavirin was estimated to be around 60%. [5]
The preliminary results indicated that 51% of patients achieved a sustained virological response [6]
Summary
The World Health Organization has declared hepatitis C a global health problem, with approximately 3% of the world’s population (roughly 170200 million people) infected with HCV. Long-term benefits of sustained virological response (SVR) are the reduction of HCV-related hepatocellular carcinoma and overall mortality. [4] In HCV G4, the most prevalent in Egypt. Sustained virological response in Egyptian patients treated with PEGIFN alfa-2a and ribavirin was estimated to be around 60%. The preliminary results indicated that 51% of patients (most with HCV genotype 4, which causes approximately 90% of HCV infections in Egypt) achieved a sustained virological response [6]. Egypt is one of the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 6.3%. DAAs open the door to decrease HCV prevalence as well as to treat infected subjects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
